Investors sell off AMD shares despite the company's pivot to life sciences AI, following a rating downgrade by HSBC that followed a six-month decline in the stock price.
Vir Biotechnology, Inc. (NASDAQ:VIR) presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid tumors, and VIR-5500, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback